What I do
Researches focused on tumor microenvironment, especially angiogenesis and lymphangiogenesis. Utilization of nanoparticles to treat refractory cancers.
From April 2008, I am involved in establishment of the new research education program for medical students in University of Tokyo.
Affiliations
Current affiliations
-
- Position
- Assistant Professor, Medical Scientist Training Program, University of Tokyo
- Company
- Department of Molecular Pathology, Graduate School of Medicine, University of Tokyo
- Duration
- 2008 - Present
- Further information
Location
- City:
- Tokyo, Tokyo-to, Japan
- Hub:
- Tokyo
Interests
I did clinical residency and wanted to know the mechanism of diseases and therapies. As a consequence, the researches I and my group conduct are basic but those to answer the questions from clinical fields.
Projects
The goal of our investigation is to develop effective treatment for refractory solid cancers.
In particular,
>Manipulating angiogenesis to optimize cancer tissue for treatment with nanoparticles (typically by using TGF-b inhibitor)
>Manipulating lymphangiogenesis to reduce metastatis
etc.
Publications
-
Enhancement of Angiogenesis Through Stabilization of Hypoxia-inducible Factor-1 by Silencing Prolyl Hydroxylase Domain-2 Gene. Molecular therapy : the journal of the American Society of Gene Therapy (2008) (Epub 20 May 2008) PubMed ID:(18500250)
-
Oka M, Iwata C, Suzuki H, Kiyono K, Morishita Y, Watabe T, Komuro A, Kano M, Miyazono K. Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis. Blood (9) , 4571-9 (2008) (Epub 29 Feb 2008) PubMed ID:(18310502)
-
Iwata C, Kano M, Komuro A, Oka M, Kiyono K, Johansson E, Morishita Y, Yashiro M, Hirakawa K, Kaminishi M, Miyazono K. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer research (21) , 10181-9 (2007) PubMed ID:(17974958)
-
Kano M, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, Fujii T, Komuro A, Kiyono K, Kaminishi M, Hirakawa K, Ouchi Y, Nishiyama N, Kataoka K, Miyazono K. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proceedings of the National Academy of Sciences of the United States of America (9) , 3460-5 (Epub 16 Feb 2007) PubMed ID:(17307870 )
-
Kano M, Morishita Y, Iwata C, Iwasaka S, Watabe T, Ouchi Y, Miyazono K, Miyazawa K. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. Journal of cell science (Pt 16) , 3759-68 PubMed ID:(16105884)
